Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 6
2008 1
2009 1
2010 1
2011 1
2013 2
2015 1
2017 2
2018 3
2019 2
2020 7
2021 5
2022 4
2023 7
2024 4
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Chu Q, et al. Among authors: cecere fl. Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931632 Clinical Trial.
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
Marinelli D, Gallina FT, Pannunzio S, Di Civita MA, Torchia A, Giusti R, Gelibter AJ, Roberto M, Verrico M, Melis E, Tajè R, Cecere FL, Landi L, Nisticò P, Porciello N, Occhipinti M, Brambilla M, Forde PM, Liu SV, Botticelli A, Novello S, Ciliberto G, Cortesi E, Facciolo F, Cappuzzo F, Santini D. Marinelli D, et al. Among authors: cecere fl. Crit Rev Oncol Hematol. 2023 Dec;192:104190. doi: 10.1016/j.critrevonc.2023.104190. Epub 2023 Oct 21. Crit Rev Oncol Hematol. 2023. PMID: 37871779 Free article.
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".
Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M, Ciardiello F, Cecere FL, Vincent M, Ferrara R, Dawe DE, Hao D, Lee CW, Morabito A, Gridelli C, Cavanna L, Iqbal M, Blais N, Leighl NB, Wheatley-Price P, Tsao MS, Ugo F, El-Osta H, Gargiulo P, Gaudreau PO, Tu D, Sederias J, Brown-Walker P, Perrone F, Seymour L, Laurie SA. Piccirillo MC, et al. Among authors: cecere fl. J Thorac Oncol. 2024 Nov;19(11):1578-1579. doi: 10.1016/j.jtho.2024.08.017. Epub 2024 Aug 24. J Thorac Oncol. 2024. PMID: 39186030 No abstract available.
Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinoma.
Gallina FT, Cecere FL, Tajè R, Bertolaccini L, Casiraghi M, Spaggiari L, Cannone G, Busetto A, Rea F, Martucci N, De Luca G, Mercadante E, Mazzoni F, Bongiolatti S, Voltolini L, Melis E, Sperduti I, Cappuzzo F, Rayes R, Ferri L, Facciolo F, Spicer J. Gallina FT, et al. Among authors: cecere fl. Eur J Cardiothorac Surg. 2024 Nov 4;66(5):ezae406. doi: 10.1093/ejcts/ezae406. Eur J Cardiothorac Surg. 2024. PMID: 39531280
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Leonetti A, Perrone F, Puntoni M, Maglietta G, Bordi P, Bria E, Vita E, Gelsomino F, De Giglio A, Gelibter A, Siringo M, Mazzoni F, Caliman E, Genova C, Bertolini F, Guaitoli G, Passiglia F, Delcuratolo MD, Montrone M, Cerea G, Pasello G, Roca E, Belluomini L, Cecere FL, Guida A, Manzo A, Adamo V, Rastelli F, Bulotta A, Citarella F, Toschi L, Zoratto F, Cortinovis DL, Berardi R, Follador A, Carta A, Camerini A, Salerno F, Silva RR, Baldini E, Cortellini A, Brighenti M, Santoni M, Malorgio F, Caminiti C, Tiseo M. Leonetti A, et al. Among authors: cecere fl. Eur J Cancer. 2024 May;202:114006. doi: 10.1016/j.ejca.2024.114006. Epub 2024 Mar 11. Eur J Cancer. 2024. PMID: 38489861
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients.
Malapelle U, Rossi G, Pisapia P, Barberis M, Buttitta F, Castiglione F, Cecere FL, Grimaldi AM, Iaccarino A, Marchetti A, Massi D, Medicina D, Mele F, Minari R, Orlando E, Pagni F, Palmieri G, Righi L, Russo A, Tommasi S, Vermi W, Troncone G. Malapelle U, et al. Among authors: cecere fl. Crit Rev Oncol Hematol. 2020 Dec;156:103118. doi: 10.1016/j.critrevonc.2020.103118. Epub 2020 Oct 3. Crit Rev Oncol Hematol. 2020. PMID: 33038627 Review.
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.
Gallina FT, Marinelli D, Tajè R, Visca P, Cecere FL, Landi L, Buglioni S, Forcella D, Melis E, Najmeh S, Rayes R, Cools-Lartigue J, Camilleri-Broët S, Fiset PO, Ferri L, Cappuzzo F, Spicer J. Gallina FT, et al. Among authors: cecere fl. Eur J Cancer. 2025 Sep 9;227:115622. doi: 10.1016/j.ejca.2025.115622. Epub 2025 Jul 10. Eur J Cancer. 2025. PMID: 40680467
48 results